Stoke Therapeutics Inc (STOK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
Stoke Therapeutics Inc (STOK) Financials: Revenue, Profit and Cash Flow
Stoke Therapeutics reported revenue of $184.42M for the fiscal year ended Dec 31, 2025, up 404.5% from the year before. That year, net income was -$6.88M with a net margin of -3.7%, operating cash flow was $45.59M and free cash flow was $44.91M. The quarter ended Sep 30, 2026 had revenue of $11.26M and net income of -$73.64M.
Revenue and Margins
The operating margin was -11.2% in the fiscal year ended Dec 2025.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $184.42M | +404.5% | 100.0% | -11.2% | -3.7% |
| Dec 2024 | $36.55M | +316.3% | 100.0% | -277.3% | -243.4% |
| Dec 2023 | $8.78M | -29.2% | 100.0% | -1307.2% | -1192.5% |
| Dec 2022 | $12.40M | N/A | 100.0% | -841.2% | -814.7% |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $184.42M | $36.55M | $8.78M | $12.40M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $113.00K |
| Gross profit | $184.42M | $36.55M | $8.78M | $12.40M | $0 | $0 | $0 | $0 | -$113.00K |
| Research and development | $137.92M | $89.13M | $82.23M | $77.84M | $54.17M | $32.20M | $23.76M | $8.37M | $3.60M |
| Operating income | -$20.59M | -$101.37M | -$114.77M | -$104.36M | -$86.06M | -$53.04M | -$35.68M | -$12.78M | -$5.55M |
| Net income | -$6.88M | -$88.98M | -$104.70M | -$101.07M | -$85.81M | -$52.24M | -$32.33M | -$12.52M | -$5.56M |
| EBITDA | -$20.00M | -$101.08M | -$112.46M | -$102.85M | -$84.81M | -$52.05M | -$35.23M | -$12.58M | -$5.44M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.26M | $9.32M | $6.23M | $1.40M | $10.63M | $13.82M | $158.57M | $22.61M | $4.89M | $4.83M | $4.22M | $2.80M |
| Gross profit | $11.26M | $9.32M | $6.23M | $1.40M | $10.63M | $13.82M | $158.57M | $22.61M | $4.89M | $4.83M | $4.22M | $2.80M |
| Operating income | -$77.31M | -$65.43M | -$53.42M | -$61.44M | -$43.09M | -$27.30M | $111.24M | -$13.65M | -$30.00M | -$29.34M | -$28.37M | -$29.59M |
| Net income | -$73.64M | -$61.62M | -$50.00M | -$57.93M | -$38.35M | -$23.48M | $112.88M | -$10.48M | -$26.43M | -$25.70M | -$26.37M | -$26.96M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $3.01M by $81.21M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $418.43M | $271.56M | $228.34M | $256.07M | $238.87M | $297.93M | $228.75M | $107.54M | $2.44M |
| Current assets | $305.70M | $232.76M | $215.34M | $244.07M | $229.22M | $293.93M | $226.03M | $106.14M | $1.91M |
| Cash and equivalents | $84.22M | $127.98M | $191.44M | $113.56M | $144.90M | $287.31M | $222.47M | $105.40M | $1.80M |
| Total liabilities | $65.98M | $42.53M | $68.78M | $71.22M | $21.09M | $11.85M | $4.32M | $2.47M | $3.73M |
| Short-term debt | $3.01M | $2.32M | $2.06M | $2.36M | $1.51M | $1.07M | N/A | $0 | $3.00M |
| Shareholder equity | $352.46M | $229.02M | $159.56M | $184.85M | $217.78M | $286.08M | $224.43M | $105.07M | -$1.29M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $406.69M | $393.97M | $443.28M | $418.43M | $360.26M | $384.51M | $406.89M | $271.56M | $293.32M | $307.76M | $205.18M | $228.34M |
| Total liabilities | $54.10M | $48.42M | $48.40M | $65.98M | $52.16M | $49.56M | $56.81M | $42.53M | $61.21M | $65.05M | $64.84M | $68.78M |
| Cash and equivalents | $107.27M | $110.00M | $155.66M | $84.22M | $83.39M | $101.47M | $274.82M | $127.98M | $150.02M | $193.48M | $178.58M | $191.44M |
| Shareholder equity | $352.59M | $345.55M | $394.88M | $352.46M | $308.11M | $334.94M | $350.07M | $229.02M | $232.11M | $242.71M | $140.34M | $159.56M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.5% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $45.59M | -$86.85M | -$81.07M | -$31.87M | -$66.91M | -$42.22M | -$31.05M | -$10.96M | -$5.38M |
| Capital expenditures | $670.00K | $203.00K | $1.62M | $3.96M | $1.20M | $1.05M | $1.64M | $935.00K | $113.00K |
| Free cash flow | $44.91M | -$87.05M | -$82.68M | -$35.83M | -$68.11M | -$43.27M | -$32.69M | -$11.90M | -$5.50M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | $306.00K | $2.46M | $378.00K | N/A |
| Investing cash flow | -$186.81M | -$107.47M | $105.95M | -$45.88M | -$76.43M | -$1.05M | -$1.63M | -$925.00K | -$113.00K |
| Financing cash flow | $97.39M | $131.09M | $53.01M | $46.41M | $1.28M | $108.11M | $149.76M | $115.64M | $5.97M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$62.69M | -$56.59M | -$60.58M | -$30.45M | -$30.37M | -$25.42M | $131.83M | -$23.19M | -$21.61M | -$17.48M | -$24.57M | -$20.65M |
| Capital expenditures | $2.85M | $1.98M | $353.00K | $232.00K | $132.00K | $154.00K | $152.00K | $42.00K | $103.00K | $46.00K | $12.00K | $229.00K |
| Free cash flow | -$65.54M | -$58.56M | -$60.94M | -$30.69M | -$30.50M | -$25.58M | $131.68M | -$23.23M | -$21.72M | -$17.52M | -$24.58M | -$20.88M |
Frequently Asked Questions About STOK
What is Stoke Therapeutics' annual revenue?
Stoke Therapeutics reported revenue of $184.42M for the fiscal year ended Dec 31, 2025.
How fast is Stoke Therapeutics' revenue growing?
Revenue was up 404.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 145.9%.
Is Stoke Therapeutics profitable?
No. Stoke Therapeutics reported net income of -$6.88M for the fiscal year ended Dec 31, 2025, with a net margin of -3.7%.
How much free cash flow does STOK generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $45.59M minus capital expenditures of $670.00K produced free cash flow of $44.91M.
How much debt does Stoke Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $3.01M and cash and equivalents of $84.22M.
STOK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors